Discover a study that has revealed a new potential mechanism of understanding inflammation in ulcerative colitis.

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrierData presented at Digestive Disease Week in San ...

New Panthers wide receiver Hunter Renfrow on Thursday discussed his battle with ulcerative colitis, a chronic inflammatory ...

To evaluate the therapeutic value of mirikizumab in IBD, researchers conducted a systematic review and meta-analysis of ...

The two major types of IBD―Crohn’s disease and ulcerative colitis―present with overlapping but distinct symptoms. Crohn’s ...

Hunter Renfrow's treatment for ulcerative colitis caused him to take a hiatus from the NFL, the Carolina Panthers' new wide ...

In 2021, Sly, biochemistry professor Harry Brumer, and a group of other researchers at the UBC developed GlycoCage, a ...

Women with the autoimmune diseases rheumatoid arthritis, lupus or systemic sclerosis may have a higher rate of death related to cardiovascular disease than men with the autoimmune diseases, according ...

Hunter Renfrow is back in the NFL after taking last season off, and now we have a better understanding of what happened.